Imidiazoles having reduced side effects

A compound selected from the group consisting of:

• wherein R1 is independently selected from the group consisting of H;
• halogen;
• C1-4 alkyl;
• C1-4 alkenyl;
• C1-4 alkynyl;
• —COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy;
• C3-6 cycloalkyl;
• aryl;
• cyano;
• nitro;
• trihalomethyl;
• oxo;
• or —(CH2)n —X—(CH2)m—(R5)o— where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is methyl or H1-2, each R6 is independent selected from the group consisting of H;
• halogen;
• C1-4 alkyl;
• C1-4 alkenyl;
• C1-4 alkynyl;
• —COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy;
• C3-6 cycloalkyl;
• aryl;
• cyano;
• nitro;
• trihalomethyl and oxo wherein each p is independently 1 or 2 and Y is —(C(R7)z)2—, wherein R7 is independently defined identically to R1 and z is independently 1 or 2, said compound further having selective agonist activity at the α2B or α2B/α2C adrenergic receptor subtype(s) over the α2A adrenergic receptor subtype, and all pharmacologically acceptable salts, esters, stereoisomers and racemic mixtures thereof.